Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Uveal Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 32fludarabine phosphate 25Peripheral Blood Stem Cell Transplantation 25Busulfan 20Antilymphocyte Serum 19Tacrolimus 15Mycophenolic Acid 15Filgrastim 15Cyclosporine 15Methotrexate 14Melphalan 12Etoposide 12pembrolizumab 11Whole-Body Irradiation 10Radiotherapy 10Methylprednisolone 10Sirolimus 9Psychiatric Rehabilitation 8Nivolumab 8Bortezomib 8fludarabine 7Prednisone 7Flow Cytometry 7sargramostim 6romidepsin 6Vorinostat 6Gemcitabine 6Doxorubicin 6Cord Blood Stem Cell Transplantation 6aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × quisinostat × Dermatologic × Clear all
NCT01486277 2016-11-03

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Janssen Research & Development, LLC

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡